Literature DB >> 12629529

Disruption and potentiation of latent inhibition by risperidone: the latent inhibition model of atypical antipsychotic action.

Ina Weiner1, Daniela Schiller, Inna Gaisler-Salomon.   

Abstract

Latent inhibition (LI), that is, retarded conditioning to a stimulus following its nonreinforced pre-exposure, is impaired in some subsets of schizophrenia patients and in amphetamine-treated rats. Potentiation of LI by antipsychotic drugs (APDs) given in conditioning, under conditions that do not lead to LI in controls, is a well-established index of antipsychotic activity. Recently, we have shown that the atypical APD, clozapine, in addition disrupts LI if administered in pre-exposure, under conditions that lead to LI in controls. This study demonstrates the same behavioral profile for the atypical APD risperidone. LI was measured in a thirst-motivated conditioned emotional response procedure by comparing suppression of drinking in response to a tone previously paired with a foot shock in rats that received nonreinforced exposure to the tone prior to conditioning (pre-exposed (PE)) and rats for whom the tone was novel (non-pre-exposed (NPE)). We show that under conditions that did not yield LI in vehicle controls (40 pre-exposures and five conditioning trials), risperidone (0.25, 0.5, and 1.2 mg/kg) led to LI when administered in conditioning. Under conditions that led to LI in vehicle controls (40 pre-exposures and two conditioning trials), risperidone (0.25, 0.5, and 2.5 mg/kg) abolished LI when administered in pre-exposure; the latter effect was not evident with haloperidol. In addition, the effects of risperidone administered in both the pre-exposure and conditioning stages were dose-dependent so that the pre-exposure-based action was manifested at lower but not at higher doses. It is concluded that atypical APDs exert in the LI model a dual pattern of effects, which enables detection of their 'typical' action (conditioning-based LI potentiation) as well as a dissociation from typical APDs by their 'atypical' action (pre-exposure-based LI disruption). It is suggested that the former and latter effects are subserved by D2 and 5HT2A antagonism, respectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12629529     DOI: 10.1038/sj.npp.1300069

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  10 in total

1.  Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

2.  In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner.

Authors:  Ramadhan Oruch; Erlend Hodneland; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2009-04-30

3.  Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia.

Authors:  Yael Piontkewitz; Michal Arad; Ina Weiner
Journal:  Schizophr Bull       Date:  2010-05-03       Impact factor: 9.306

4.  Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia.

Authors:  Tatiana Lipina; Viviane Labrie; Ina Weiner; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

5.  Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia?

Authors:  Mariana Bendlin Calzavara; Wladimir Agostini Medrano; Raquel Levin; Sonia Regina Kameda; Monica Levy Andersen; Sergio Tufik; Regina Helena Silva; Roberto Frussa-Filho; Vanessa Costhek Abílio
Journal:  Schizophr Bull       Date:  2008-02-16       Impact factor: 9.306

6.  Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered.

Authors:  I Gaisler-Salomon; L Diamant; C Rubin; I Weiner
Journal:  Psychopharmacology (Berl)       Date:  2007-10-11       Impact factor: 4.530

7.  Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action.

Authors:  Cecilie Bay-Richter; Colm M P O'Tuathaigh; Gerard O'Sullivan; David M Heery; John L Waddington; Paula M Moran
Journal:  Int J Neuropsychopharmacol       Date:  2008-11-17       Impact factor: 5.176

8.  Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia.

Authors:  L Zuckerman; N Rimmerman; I Weiner
Journal:  Psychopharmacology (Berl)       Date:  2003-06-24       Impact factor: 4.530

9.  Selective effects of D- and L-govadine in preclinical tests of positive, negative, and cognitive symptoms of schizophrenia.

Authors:  Christopher C Lapish; Kee-Chan Ahn; R Andrew Chambers; Donovan M Ashby; Soyon Ahn; Anthony G Phillips
Journal:  Neuropsychopharmacology       Date:  2014-01-30       Impact factor: 7.853

10.  Effects of N-acetylcysteine on amphetamine-induced sensitization in mice.

Authors:  Ana P Herrmann; Roberta Andrejew; Radharani Benvenutti; Clarissa S Gama; Elaine Elisabetsky
Journal:  Braz J Psychiatry       Date:  2017-12-11       Impact factor: 2.697

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.